Adalimumab, a tumor necrosis factor inhibitor, was associated with an early reduction in epicardial adipose tissue in people ...

Moonwalk Biosciences has raised an oversubscribed $70 million Series B financing to advance its pipeline of adipose-targeted RNA interference medicines for obesity and cardiometabolic diseases. The ...

MEXICO CITY — Researchers presented findings on adipose tissue at the 2026 International Congress on Obesity (ICO), held by the World Obesity Federation. By studying adipose tissue as an endocrine ...

Obesity is a growing global health problem, the prevalence of which has tripled since 1975. It currently affects 650 million people worldwide, and in Spain the prevalence among adults is 28%. This ...

Obesity is a global health concern closely linked to a range of metabolic diseases, such as type 2 diabetes and cardiovascular diseases. A research team from the Department of Pharmacology and ...

The funds will support efforts to advance its lead candidate into human clinical trials in 2027, and expand its pipeline of ...

The common forms of type 2 diabetes are caused by a constellation of genetic and epigenetic factors and molecular changes related to diet; lifestyle, including lack of exercise and sleep; ...

New cells discovered in human omental adipose tissue inhibit fat cell formation, revealing why 'apple' body shapes may pose higher metabolic health risks. Understanding how fat tissue forms and ...

The worldwide obesity crisis has become a dominant public health crisis across the globe. Over 3 billion people worldwide ...

Moonwalk Biosciences, a biotechnology company developing first-in-class adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases, today announced the closing of an ...